查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835464

肝纤维化治疗市场（依药物类别、作用机制、给药途径和通路）－全球预测 2025-2032

Liver Fibrosis Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年肝纤维化治疗市场将成长至 337 亿美元，复合年增长率为 10.12%。

主要市场统计数据
基准年2024年 155.7亿美元
预计2025年 171.2亿美元
预测年份：2032年 337亿美元
复合年增长率（%） 10.12%

对治疗、监管和商业性格局的进展以及肝纤维化药物开发和相关人员进行权威介绍

肝纤维化是尚未满足的临床需求、科学创新和商业机会的关键交会点。过去十年，创伤治疗、细胞外基质重塑和免疫代谢的进展已将纤维化进展重新定义为一个可控制的治疗标靶，而非不可避免的临床终点。这种模式转移带来了更多样化的治疗方法，促进了肝病学和免疫学专家之间的跨学科合作，并强化了将机制与临床结果联繫起来的转化生物标记的重要性。

临床医生、付款人和开发者目前专注于通用的优先事项：提高诊断准确性、在疾病发展过程中更早地进行干预，以及在确保长期用药安全性的同时，证明纤维化的持久逆转。同时，监管机构也表现出愿意接受新的终点和适应性试验设计，前提是采用经过严格检验的替代。这些动态创造了一个复杂的环境，在这个环境中，科学前景必须与供应链弹性和报销途径等营运现实相平衡。

本报告重点关注新兴疗法、平台技术和相关人员奖励如何相互作用以形成发展策略，旨在提供清晰、可操作的综合方案，以协助必须同时应对科学复杂性、监管细微差别和商业性要求的决策者。

科学突破、扩展模式和创新试验设计如何推动肝纤维化治疗策略和相关人员行为的根本变化

在科学突破、治疗模式多样化和临床试验架构变革的推动下，肝纤维化的模式正在发生重大转变。纤维化讯号网络的分子阐明使得标靶辨识更加精准，生物製药、细胞和基因治疗以及小分子药物设计的进步也扩展了治疗套件。随着治疗方法日益多样化，研发人员越来越多地根据疾病表型调整治疗促进要素，优先考虑调节纤维化核心驱动因素的药物，而非仅仅广泛抑制相关发炎。

临床试验设计和患者识别领域的创新也正在重塑临床开发。非侵入性诊断和数位生物标记物正在推动更早的入组和更有效率的生物效应评估。这些工具有助于缩短概念验证试验的时间，提高资讯量，从而降低风险并加快「通过/不通过」的决策。同时，产学伙伴关係也变得越来越重要，将具有互补专业知识和能力的团队结合起来，以应对复杂的转化挑战。

商业性来看，定价和可及性策略正随着差异化治疗方法的出现而不断演变。付款方更重视透过真实世界证据和持续的临床效用来证明价值，而申办者则在研发早期就将卫生经济学和疗效研究纳入其中。总而言之，这些转变标誌着一个日趋成熟的领域，其中科学创新正日益与务实、注重疗效的研发路径相结合。

评估近期美国关税政策的变化如何改变肝纤维化药物开发商的供应链弹性、筹资策略和商业规划

美国近期的关税政策变化，使支持药品开发和商业化的全球供应链变得更加复杂。关税调整不仅影响了原料药的采购，也影响了专用生技药品生产投入的采购。依赖跨境采购的製造商必须重新评估供应商合约、库存策略和成本结构，以保持供应的连续性并保护利润率。

为了应对这种情况，许多公司正在多元化供应商基础、将关键製造流程分包出去或扩大关键原材料的库存，以缓解中断的影响。这些营运转变也影响着外包决策和製造外包关係，促进了更紧密的合作，并提高了前置作业时间和产能限制的透明度。同时，监管团队正在管理製造地变更对产品标籤、进口文件和品质监管的影响。

策略定价和报销谈判也受到了类似的影响，商业团队正在重新调整其上市策略，以应对到岸成本的潜在成长。同时，整个价值链上的相关人员高度重视供应链弹性、双重采购和情境规划。总而言之，这些变化凸显了整合监管、营运和商业规划的重要性，以便在不断变化的贸易政策中保持临床发展势头并确保患者获得药物。

将药物类别、作用机制、给药途径和分销管道联繫起来的多维细分洞察，为开发和商业化策略提供讯息

了解细分市场对于将研究和商业策略与治疗机会相结合至关重要。治疗药物可依药物类别分类，涵盖生物製剂、细胞疗法、基因疗法和小分子抑制剂。小分子抑制剂包括天然产物衍生的骨架和合成优化的化合物，这些化合物可口服给药并进入细胞内标靶。

基于机制的细分透过突出 ASK1 抑制剂、半乳糖凝集素 3 抑制剂、PPAR促效剂和 TGFβ 阻断剂作为不同的机制方法，进一步细化了优先顺序。 PPAR 轴本身细分为 PPARα、PPARδ 和 PPARγ，每种轴都表现出不同的代谢和纤维化生物学特性，可根据患者的表型和合併症情况进行客製化。给药途径对于依从性和慢性治疗方案至关重要。静脉或皮下注射疗法往往支持受控药物动力学和基于临床的给药模式，而口服製剂则有利于门诊病人管理和更广泛的应用。

分销管道影响商业性执行和病患可及性。医院药房为急诊和住院患者提供复杂的生物製药和输液疗法；在线药房为稳定的慢性病治疗方案提供便利性和连续性；零售药房（包括连锁药房和独立药房）则为门诊配药和直接面向患者提供便利。这些相互交织的细分视角提供了一个多维框架，用于确定开发优先顺序、设计临床方案以及製定反映药物形态、机制、给药途径和分销现状的上市策略。

区域发展和准入动态影响全球多个医疗保健生态系统的监管参与、证据生成和商业性执行

区域动态对研发重点、监理参与度和商业性取得途径有重大影响。在美洲，监管机构和付款方强调真实世界疗效和基于价值的合同，奖励申办方设计能够证明持续临床疗效并降低医疗成本的证据生成策略。全部区域的临床网络和学术中心也为患者招募和生物标记检验工作做出了贡献，形成了早期试验设计和转化研究合作。

在欧洲、中东和非洲，监管协调工作和多样化的医疗保健服务模式要求采用独特的临床试验实施和市场准入规划方法。虽然欧洲的监管途径通常优先考虑可比性和效益提升的证明，但卫生技术评估流程的地区差异意味着证据包必须根据当地付款人的期望进行量身定制。在中东和非洲部分地区，基础设施限制和不同的使用模式影响实施研究和可近性计画的设计。

亚太地区拥有多样化的临床和商业环境，包括强大的生技药品生产能力、不断增长的临床试验能力以及快速普及的数位医疗工具。各国的法规和报销途径要求儘早与当地相关人员沟通。综合来看，这些区域特征凸显了製定适应性监管策略、兼顾文化差异的病人参与以及与该地区支付方和医疗服务提供者优先事项相一致的证据计划的必要性。

各公司的策略、伙伴关係和平台能力如何整合，以推进肝纤维化治疗的差异化产品线和协作方式

各公司在肝纤维化领域的策略特点是平台主导创新、有针对性的产品开发和策略合作相结合。生技公司正在利用灵活的转化医学产品线和有针对性的患者识别策略，推动差异化机制和First-in-Class药物的研发。大型製药公司也越来越多地寻求与创新者合作，以获得规模、监管经验和商业化基础设施，从而加速后期开发并扩大其治疗组合。

委外研发机构)和合约开发与生产组织 (CDMO) 在加快生物製药和小分子药物专案的研发进度和提升产能方面发挥关键作用。这些合作伙伴支持灵活的研究设计、复杂的供应链协调以及跨司法管辖区的监管申报。策略联盟、授权协议和共同开发契约屡见不鲜，将小型研发机构的科学研究创新能力与成熟企业的商业性和监管能力结合。

纵观竞争格局，差异化将源自于能否展现临床疗效、适合长期用药的安全性，以及透过经过验证的生物标记展示机制参与的能力。整合转化科学、以患者为中心的临床试验设计和稳健的商业计划的公司，将能够更有效地应对复杂的报销流程和相关人员的期望。我们强调合作而非正面竞争，这反映了应对纤维化疾病生物学问题的复杂性以及互补能力的价值。

实际可行的策略性倡议，将转化生物标记、供应链弹性、区域监管参与和伙伴关係模式结合起来，推动治疗药物的成功上市

行业领导者应优先考虑一系列切实可行的倡议，将科学前景与营运和商业现实相结合。首先，儘早整合转化生物标记策略，以降低临床计画风险，并确保作用机制与临床终点之间的明确关联。这种整合将有助于与监管机构的对话，并强化对付款人的价值提案。其次，投资于供应链的韧性，包括实现关键投入的供应商多元化、评估区域製造方案以及製定紧急时应对计画，以保持临床和商业性的连续性。

新兴创新者应寻求合作伙伴进行后期开发和商业化，而现有企业则可以透过有针对性的授权合约和共同开发契约来加速创新。第四，使区域策略与当地监管环境和付款人保持一致，并与卫生技术评估组织和区域临床网路合作，以确保证据包符合当地要求。最后，设计反映给药途径和分销动态的商业模式：确保为注射疗法提供适当的临床支持，并为口服疗法提供顺畅的零售和线上履约。

透过实施这些建议，组织可以将科学进步转化为持续的临床影响，同时管理营运复杂性并奖励相关人员，使其与开发和商业化路径保持一致。

结合专家初步访谈、系统性的二次文献综述和商业分析的严格混合方法研究途径将检验治疗和商业见解

本报告背后的研究融合了多种调查方法，以确保其观点的可靠性和实证性。主要研究包括对肝病临床专家、监管顾问、行业高管和供应链专业人士的结构化访谈，以了解当前的实践模式、监管预期和营运限制。这些定性见解被整合在一起，以理解不同治疗方法的差异化，并揭示影响开发和商业化策略的决策点。

二次研究包括对同行评审文献、临床试验註册库和公开的监管指南进行系统性回顾，以阐明机制原理、临床终点和转化生物标记。营运分析利用产业报告，包括生产能力、供应链框架和分销模式，评估其对研发和上市的实际影响。在整个过程中，我们运用证据三角检定来验证结论，并确保解读能反映多种观点。

透过由领域专家和跨职能评审员反覆检验，确保分析的严谨性。该方法优先考虑清晰度和可重复性，并专注于将机制科学与临床试验设计和商业性执行相结合。这种方法支持决策者基于科学证据和可行性寻求可操作的资讯。

结论性综合强调了在科学、临床开发、运作和商业性执行方面可采取的优先事项，以实现肝纤维化的持续治疗效益

摘要：肝纤维化治疗领域正从概念走向实际应用。生物目标和模态工程的科学进步正在拓展可行的治疗方法，而诊断和检测设计的创新则使概念验证更有效率。同时，从供应链转移到与关税相关的采购考量，研发、製造和商业团队需要进行一体化规划。

在这种环境下取得成功，取决于将机制理解与转化生物标誌物相结合，设计以患者为中心的临床项目，以反映给药途径和药物分配的实际情况，并儘早透过强有力的证据策略与付款方和监管机构进行沟通。策略联盟和适应性营运模式将是关键的推动因素，使组织能够将科学差异化与规模化和市场化专业知识相结合。

本报告始终倡导以结果为导向的方法，强调可衡量的临床效益、持续的患者疗效以及切实可行的获取途径。那些拥抱数据驱动型开发、优先考虑供应链韧性、并寻求与其内部能力互补的伙伴关係关係的相关人员，将最有能力将科学创新转化为持续的临床和商业性成功。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 一种针对肝纤维化患者的发炎和纤维化的新型联合治疗
  • 非侵入性成像生物标记的进展加速了肝纤维化进展的早期检测
  • 在开发治疗肝纤维化的药物时，使用基因组和代谢生物标记的分层临床试验设计来选择患者
  • 监管进展支持加速肝病治疗中新型抗纤维化药物的核准途径
  • 生技公司与学术机构进行策略合作，共同探索下一代纤维化抑制剂
  • 在慢性肝纤维化治疗方法中，口服小分子疗法的应用日益增多，而非注射剂
  • 纤维化药物的高定价策略和受报销政策变化影响的市场进入挑战
  • 整合数位健康解决方案，实现肝纤维化治疗反应的远端监控
  • 来自纵向疾病登记的真实世界证据塑造了临床指南和市场渗透策略

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 肝纤维化药物市场（依药物类别）

  • 生物治疗
    • 单株抗体
    • 重组蛋白
  • 细胞疗法
  • 基因治疗
  • 小分子抑制剂
    • 天然产品
    • 合成化合物

9. 肝纤维化药物市场（依作用机转）

  • ASK1抑制剂
  • 半乳糖凝集素-3抑制剂
  • PPAR促效剂
    • 过氧化物酶体增殖物激活受体α
    • Delta
    • 过氧化物酶体增殖物激活受体γ
  • TGF-β阻断剂

第 10 章肝纤维化药物市场（依给药途径）

  • 注射
    • 静脉
    • 皮下
  • 口服

第11章肝纤维化药物市场按分销管道

  • 医院药房
  • 网路药局
  • 零售药局
    • 连锁药局
    • 独立药房

第十二章肝纤维化药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章肝纤维化药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章肝纤维化药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc.
    • Intercept Pharmaceuticals, Inc.
    • Madrigal Pharmaceuticals, Inc.
Product Code: MRR-437A5D08AE2D

The Liver Fibrosis Drugs Market is projected to grow by USD 33.70 billion at a CAGR of 10.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 15.57 billion
Estimated Year [2025] USD 17.12 billion
Forecast Year [2032] USD 33.70 billion
CAGR (%) 10.12%

An authoritative introduction to the evolving therapeutic, regulatory, and commercial context shaping liver fibrosis drug development and stakeholder priorities

Liver fibrosis occupies a pivotal intersection of unmet clinical need, scientific innovation, and commercial opportunity. Over the past decade, advances in understanding wound healing, extracellular matrix remodeling, and immunometabolism have reframed fibrotic progression as a tractable therapeutic target rather than an inexorable clinical endpoint. This paradigm shift has catalyzed more diverse therapeutic modalities, encourages cross-disciplinary collaboration between hepatology and immunology experts, and elevates the importance of translational biomarkers that link mechanism to clinical outcomes.

Clinicians, payers, and developers now converge on common priorities: improving diagnostic precision, intervening earlier in the disease course, and demonstrating durable reversal of fibrosis while ensuring safety for chronic administration. Concurrently, regulatory agencies are signaling a willingness to engage on novel endpoints and adaptive trial designs, contingent on rigorously validated surrogate measures. These dynamics create a complex environment where scientific promise must be balanced against operational realities such as supply chain resilience and reimbursement pathways.

Throughout this report, emphasis is placed on how emerging therapies, platform technologies, and stakeholder incentives interact to shape development strategies. The intent is to provide a clear, actionable synthesis that supports decision-makers who must navigate scientific complexity, regulatory nuance, and commercial imperatives simultaneously.

How scientific breakthroughs, modality expansion, and innovative trial designs are driving a fundamental transformation in liver fibrosis therapeutic strategies and stakeholder behavior

The liver fibrosis landscape is undergoing transformative shifts driven by scientific breakthroughs, modality diversification, and changes in clinical trial architecture. Molecular deconvolution of fibrogenic signaling networks has enabled more precise target identification, while advances in biologics, cell and gene therapies, and small molecule design have expanded the therapeutic toolkit. As modalities diversify, developers are increasingly matching mechanism to disease phenotype, prioritizing agents that modulate core drivers of fibrogenesis rather than broadly suppressing associated inflammation.

Clinical development is also being reshaped by innovations in trial design and patient identification. Noninvasive diagnostics and digital biomarkers are enabling earlier enrollment and more efficient assessment of biological effect. These tools facilitate shorter, more informative proof-of-concept studies that reduce risk and accelerate go/no-go decisions. At the same time, partnerships across industry, academia, and contract research organizations are growing in importance as teams combine complementary expertise and capabilities to address complex translational challenges.

Commercially, pricing and access strategies are evolving in tandem with therapeutic differentiation. Payers are focusing on value demonstration through real-world evidence and durable clinical benefit, which is prompting sponsors to incorporate health economics and outcomes research earlier in development. Taken together, these shifts indicate a maturing field where scientific innovation is increasingly paired with pragmatic, outcome-focused development pathways.

Assessing how recent United States tariff shifts have reshaped supply chain resilience, sourcing strategies, and commercial planning across liver fibrosis drug development

Recent tariff policy developments in the United States have introduced a layer of complexity to the global supply chains that underpin drug development and commercialization. Tariff adjustments affect both the procurement of active pharmaceutical ingredients and the sourcing of specialized biologics manufacturing inputs. Manufacturers that rely on cross-border component sourcing have needed to reassess supplier contracts, inventory strategies, and cost structures in order to preserve supply continuity and protect margins.

In response, many organizations have diversified their supplier base, reshored critical manufacturing steps, or expanded inventories of key raw materials to mitigate disruption. These operational shifts have also influenced outsourcing decisions and relationships with contract development and manufacturing organizations, prompting tighter collaboration and increased transparency around lead times and capacity constraints. Regulatory teams, in parallel, are managing the implications for product labeling, import documentation, and quality oversight when manufacturing footprints change.

Strategic pricing and reimbursement discussions have been affected as well, with commercial teams recalibrating launch strategies to account for potential increases in landed costs. Meanwhile, stakeholders across the value chain are placing higher priority on supply chain resilience, dual sourcing, and scenario planning. Collectively, these changes underscore the importance of integrating regulatory, operations, and commercial planning to maintain clinical momentum and ensure patient access amid evolving trade policies.

Multidimensional segmentation insights that connect drug class, mechanism of action, administration route, and distribution channels to inform development and commercialization strategy

Understanding segmentation is essential to aligning research and commercial strategies with therapeutic opportunity. When therapies are organized by drug class, the field spans biologic therapies, cell therapies, gene therapies, and small molecule inhibitors. Within the biologic category, attention centers on monoclonal antibodies and recombinant proteins as platforms that offer target specificity and modulated immune engagement, while small molecule inhibitors encompass both natural product-derived scaffolds and synthetically optimized compounds that enable oral dosing and intracellular target access.

Mechanism-based segmentation further refines prioritization by highlighting ASK1 inhibitors, galectin-3 inhibitors, PPAR agonists, and TGF beta blockers as distinct mechanistic approaches. The PPAR axis itself is subdivided into PPAR alpha, PPAR delta, and PPAR gamma, each presenting differentiated metabolic and fibrotic biology that can be matched to patient phenotypes and comorbidity profiles. Route of administration matters for adherence and chronic treatment planning; injectable therapies, administered either intravenously or subcutaneously, tend to support controlled pharmacokinetics and clinic-based dosing models, whereas oral formulations facilitate outpatient management and broader uptake.

Distribution channels influence commercial execution and patient access. Hospital pharmacies serve acute and inpatient settings where complex biologics and infusion therapies are delivered, online pharmacies enable convenience and continuity for stable chronic regimens, and retail pharmacies-comprising chain and independent outlets-drive outpatient dispensing and direct-to-patient accessibility. Together, these intersecting segmentation lenses offer a multidimensional framework to prioritize development, design clinical programs, and craft go-to-market strategies that reflect modality, mechanism, administration route, and distribution realities.

Regional development and access dynamics that shape regulatory engagement, evidence generation, and commercial execution across multiple global healthcare ecosystems

Regional dynamics exert a profound influence on development priorities, regulatory engagement, and commercial access pathways. In the Americas, regulatory agencies and payers emphasize real-world effectiveness and value-based contracting, which incentivizes sponsors to design evidence generation strategies that demonstrate durable clinical outcomes and cost-of-care impacts. Clinical networks and academic centers across the region also contribute to patient recruitment and biomarker validation efforts, shaping early-phase study design and translational research collaborations.

Across Europe, Middle East & Africa, regulatory harmonization efforts and varying healthcare delivery models require tailored approaches to clinical trial execution and market access planning. European regulatory pathways often prioritize comparability and demonstration of incremental benefit, while regional variations in health technology assessment processes mean that evidence packages must be calibrated to local payer expectations. In parts of the Middle East and Africa, constrained infrastructure and differing prevalence patterns influence the design of implementation studies and access programs.

The Asia-Pacific region presents diverse clinical and commercial environments, with strong capabilities in biologics manufacturing, growing clinical trial capacity, and rapid adoption of digital health tools. Country-specific regulations and reimbursement pathways necessitate early engagement with local stakeholders. Taken together, these regional contours underscore the need for adaptive regulatory strategies, culturally informed patient engagement, and evidence plans that align with payer and provider priorities across geographies.

How company strategies, partnerships, and platform capabilities are converging to drive differentiated pipelines and collaborative approaches in liver fibrosis therapeutics

Company strategies in liver fibrosis are characterized by a mix of platform-driven innovation, targeted product development, and strategic collaboration. Biotech firms are advancing differentiated mechanisms and first-in-class assets, leveraging nimble translational pipelines and focused patient-identification strategies. Larger pharmaceutical companies contribute scale, regulatory experience, and commercialization infrastructure, and increasingly seek partnerships with innovators to accelerate late-stage development and broaden therapeutic portfolios.

Contract research organizations and contract development and manufacturing organizations play a critical role in accelerating timelines and enabling flexible capacity for both biologics and small molecule programs. These partners support adaptive trial designs, complex supply chain coordination, and regulatory submissions across multiple jurisdictions. Strategic alliances, licensing agreements, and co-development deals are common as organizations combine strengths: scientific ingenuity from smaller developers paired with commercial and regulatory capabilities from established firms.

Across the competitive landscape, differentiation arises from clinical efficacy signals, safety profiles amenable to chronic administration, and the ability to demonstrate mechanistic engagement through validated biomarkers. Companies that integrate translational science, patient-centric trial designs, and robust commercial planning are positioned to navigate reimbursement complexities and stakeholder expectations more effectively. The emphasis on collaboration, rather than purely head-to-head competition, reflects the complexity of addressing fibrotic disease biology and the value of complementary capabilities.

Actionable strategic initiatives that align translational biomarkers, supply chain resilience, regional regulatory engagement, and partnership models to accelerate successful therapeutic launches

Industry leaders should prioritize a set of actionable initiatives that align scientific promise with operational and commercial realities. First, integrate translational biomarker strategies early to de-risk clinical programs and create clear links between mechanism of action and clinical endpoints. This alignment will facilitate regulatory dialogue and strengthen value propositions for payers. Second, invest in supply chain resilience by diversifying suppliers for critical inputs, evaluating regional manufacturing options, and establishing contingency plans that preserve clinical and commercial continuity.

Third, pursue strategic collaborations that combine complementary capabilities: emerging innovators should seek partners for late-stage development and commercialization, while established companies can accelerate innovation through targeted licensing and co-development agreements. Fourth, tailor regional strategies to local regulatory and payer landscapes, engaging health technology assessment bodies and regional clinical networks to ensure evidence packages meet local requirements. Finally, design commercial models that reflect route of administration and distribution dynamics: ensure appropriate clinic-based support for injectable therapies and frictionless retail and online fulfillment for oral regimens.

By executing these recommendations, organizations can translate scientific advances into durable clinical impact while managing operational complexity and aligning stakeholder incentives across development and commercialization pathways.

A rigorous mixed-methods research approach combining expert primary interviews, systematic secondary literature review, and operational analysis to validate therapeutic and commercial insights

The research behind this report combines multiple methodological approaches to ensure a robust and evidence-based perspective. Primary research included structured interviews with clinical experts in hepatology, regulatory advisors, industry executives, and supply chain specialists to capture current practice patterns, regulatory expectations, and operational constraints. These qualitative insights were synthesized to contextualize therapeutic differentiation and to illuminate decision points that influence development and commercialization strategies.

Secondary research encompassed a systematic review of peer-reviewed literature, clinical trial registries, and publicly available regulatory guidance to map mechanistic rationales, clinical endpoints, and translational biomarkers. Operational analysis leveraged industry reports on manufacturing capabilities, supply chain frameworks, and distribution models to assess practical implications for development and market entry. Throughout the process, triangulation of evidence was applied to validate conclusions and to ensure that interpretations reflected multiple perspectives.

Analytical rigor was maintained through iterative validation with subject matter experts and cross-functional reviewers. The methodology prioritized clarity and reproducibility, with an emphasis on linking mechanistic science to clinical trial design and commercial execution. This approach supports decision-makers seeking actionable intelligence grounded in both scientific evidence and operational feasibility.

A conclusive synthesis highlighting actionable priorities across science, clinical development, operations, and commercial execution to realize durable therapeutic impact in liver fibrosis

In summary, the liver fibrosis therapeutic landscape is transitioning from conceptual promise to pragmatic execution. Scientific advances in target biology and modality engineering have expanded the set of viable interventions, while innovations in diagnostics and trial design are enabling more efficient proof-of-concept work. At the same time, operational pressures-ranging from supply chain shifts to tariff-related sourcing considerations-require integrated planning across R&D, manufacturing, and commercial teams.

Success in this environment will hinge on the ability to align mechanistic clarity with translational biomarkers, to design patient-centric clinical programs that reflect route of administration and distribution realities, and to engage payers and regulators early with robust evidence strategies. Strategic collaborations and adaptive operational models will be key enablers, allowing organizations to combine scientific differentiation with scale and market access expertise.

The outcome-oriented approach advocated throughout this report emphasizes measurable clinical benefit, durable patient outcomes, and pragmatic pathways to access. Stakeholders that adopt data-driven development, prioritize supply chain resilience, and pursue partnerships that complement internal capabilities will be best positioned to convert scientific innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging combination therapies targeting inflammation and fibrogenesis in liver fibrosis patients
  • 5.2. Advances in noninvasive imaging biomarkers accelerating early detection of liver fibrosis progression
  • 5.3. Stratified clinical trial designs leveraging genomic and metabolic biomarkers for patient selection in liver fibrosis drug development
  • 5.4. Regulatory momentum behind accelerated approval pathways for novel antifibrotic agents in hepatic disease management
  • 5.5. Strategic partnerships between biotech firms and academic centers driving discovery of next generation fibrogenesis inhibitors
  • 5.6. Rising adoption of oral small molecule therapies over injectables in chronic liver fibrosis treatment regimens
  • 5.7. Market access challenges influenced by high pricing strategies and evolving reimbursement policies for fibrosis drugs
  • 5.8. Integration of digital health solutions enabling remote monitoring of treatment response in liver fibrosis therapies
  • 5.9. Real world evidence from longitudinal disease registries shaping clinical guidelines and market penetration strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Fibrosis Drugs Market, by Drug Class

  • 8.1. Biologic Therapies
    • 8.1.1. Monoclonal Antibodies
    • 8.1.2. Recombinant Proteins
  • 8.2. Cell Therapies
  • 8.3. Gene Therapies
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. Natural Products
    • 8.4.2. Synthetic Compounds

9. Liver Fibrosis Drugs Market, by Mechanism Of Action

  • 9.1. ASK1 Inhibitors
  • 9.2. Galectin-3 Inhibitors
  • 9.3. PPAR Agonists
    • 9.3.1. PPAR Alpha
    • 9.3.2. PPAR Delta
    • 9.3.3. PPAR Gamma
  • 9.4. TGF Beta Blockers

10. Liver Fibrosis Drugs Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral

11. Liver Fibrosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Liver Fibrosis Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Liver Fibrosis Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Liver Fibrosis Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Gilead Sciences, Inc.
    • 15.3.2. AbbVie Inc.
    • 15.3.3. F. Hoffmann-La Roche Ltd.
    • 15.3.4. Bristol-Myers Squibb Company
    • 15.3.5. Pfizer Inc.
    • 15.3.6. Novartis AG
    • 15.3.7. Takeda Pharmaceutical Company Limited
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Intercept Pharmaceuticals, Inc.
    • 15.3.10. Madrigal Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032